Stocksigma LogoStocksigma Logo

Novyra Pharmachem Reports Q1FY27 Loss on Strong Pharma Segment Revenue Growth

Novyra Pharmachem reported a net loss of ₹1.99 Lakhs for Q1FY27, a slight improvement from a ₹533.83 Lakh loss in Q4FY26 but worse than the ₹0.77 Lakh loss

Novyra Pharmachem Reports Q1FY27 Loss on Strong Pharma Segment Revenue Growth

Bansisons Tea Industries Ltd · Financial Result · 14 Aug 2026, 11:43 pm

Novyra Pharmachem Reports Q1FY27 Loss on Strong Pharma Segment Revenue Growth Novyra Pharmachem reported a net loss of ₹1.99 Lakhs for Q1FY27, a slight improvement from a ₹533.83 Lakh loss in Q4FY26 but worse than the ₹0.77 Lakh loss in Q1FY26. Revenue from operations surged to ₹172.61 Lakhs, up significantly from ₹3.00 Lakhs YoY and ₹10.44 Lakhs QoQ. The growth was driven by the Pharma segment, which generated ₹172.61 Lakhs in revenue and a profit of ₹1.29 Lakhs. The overall loss was due to large losses in the now-discontinued Tea Estate segment in previous periods.

Original exchange filing (PDF)

More announcements from Bansisons Tea Industries Ltd

All Bansisons Tea Industries Ltd announcements